Schwartz Elissa J. 4

What Happened

• Elissa J. Schwartz, a director of Galectin Therapeutics, was granted 60,000 stock options (reported as a derivative acquisition) on January 16, 2026. The options are reported at $0.00 in the filing and were issued under the company's 2019 Omnibus Equity Incentive Plan. This was an awards/grant transaction (not a market purchase or sale) — i.e., compensation rather than an outright buy or sale of existing shares.

Key Details

• Transaction date: 2026-01-16; Form 4 filed: 2026-01-21 (filed late relative to the usual 2-business-day requirement).
• Security: 60,000 stock options (derivative), reported price $0.00.
• Vesting: 100% on December 31, 2026 (per footnote).
• Plan: Issued under Galectin Therapeutics, Inc. 2019 Omnibus Equity Incentive Plan.
• Shares owned after transaction: Not specified in the provided excerpt.
• Accession #: 0001133416-26-000022.

Context

• These are option awards (derivative securities), not immediate common-share ownership. The options vest in full at year-end 2026; until exercised, they do not represent shares you can trade. Grants are commonly used for director compensation and do not alone indicate buying or selling sentiment. The late filing reduces short-term transparency but does not change the nature of the grant.